

AXIS Capital Holdings Limited and PartnerRe Ltd Merger Call

Company Participants

- Albert A. Benchimol
- Linda Ventresca
- Michael A. Butt

Other Participants

- Amit Kumar
- Brian R. Meredith
- Charles J. Sebaski
- Ian J. Gutterman
- Jay Arman Cohen
- Josh D. Shanker
- Meyer Shields

MANAGEMENT DISCUSSION SECTION

Operator

Welcome to the AXIS Capital PartnerRe amalgamation update conference call. All participants will be in listen-only mode.

After today's presentation, there will be an opportunity to ask questions.

Please also note, today's event is being recorded. I would now like to turn the conference over to Linda Ventresca, Executive Vice President. Ms. Ventresca, please go ahead ma'am.

Linda Ventresca {BIO 5930519 <GO>}

Thank you, Rocco and good morning, ladies and gentlemen.

I am happy to welcome you to our conference call to discuss an update with respect to the merger between AXIS Capital and PartnerRe, as you've seen our press release that was issued this morning.

We've also posted to the investor information section of our website the presentation for today. We set aside an hour for today's call, which is also available as audio webcast through the AXIS Capital website. A replay of the teleconference will be available by

dialing 877-344-7529 in the United States. The international number is 412-317-0088. The conference code for both replay dial-in numbers is 10065518.

On today's call are Michael Butt, Chairman of the Board of AXIS Capital; Albert Benchimol, President and CEO of AXIS Capital; and Joseph Henry, CFO of AXIS Capital.

Before I turn the call over to Michael, I will remind everyone that the statements made during this call, including the question-and-answer session, which are not historical facts, may be forward-looking statements within the meaning of the U.S. federal securities laws.

These forward-looking statements, which are subject to risks, uncertainties and assumptions about PartnerRe and AXIS, may include projections of their respective future financial performance, their respective anticipated growth strategies and anticipated trends in their respective businesses. These statements are only predictions based on current expectations and projections about future events.

There are important factors that could cause actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements, as are further described in the risk factors set forth in AXIS's most recent report on Form 10-K and our other documents on file with the SEC. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.

For information about the pending merger, please see our merger proxy S4 filed on March 16, 2015 or visit the investor information section of our website, www.axiscapital.com.

With that I'd like to turn the call over to Michael Butt.

Michael A. Butt {BIO 1750135 <GO>}

Thank you very much, Linda. Good morning, everyone and thank you for joining us today.

As Linda said, I'm here today with Albert Benchimol and Joe Henry. And it is indeed my great pleasure to be here again to talk with you about this transformative combination.

As we explained when we announced this merger in January, combining our two companies will create a broadly diversified global specialty insurance and reinsurance company with the scale, capital and market presence to compete at the highest levels of our industry internationally.

Our board has always been focused on addressing the challenges of today's evolving markets and creating value for our shareholders. Our combined entity will be one of the world's preeminent specialty insurance and reinsurance companies. We will have a top-five market position among reinsurers and a leading position among broker-based

reinsurers. We will have a significant specialty insurance platform with compelling growth prospects across a diversified array of product lines and a strong and growing life, accident, and health franchise.

Although both PartnerRe and AXIS are well-positioned on their own, we believe that we will be better positioned to compete and excel in this evolving new global marketplace as a combined entity, which will benefit our clients, our brokers, our shareholders and our employees.

I have always had a great deal of admiration for PartnerRe and the business they've built in the reinsurance market over the past two decades since I came to Bermuda at the same time that PartnerRe was being formed. Our work with them during this integration process over the past few months has strongly reinforced these sentiments.

As Chairman Emeritus of the combined organization I look forward to working with our talented group of leaders from both of these great organizations and serving the combined company. I'd now like to turn the call over to Albert, who will discuss the specifics of this revised transaction. Albert?

Albert A. Benchimol {BIO 2023727 <GO>}

Thank you Michael, and good morning everyone.

We've been working closely with PartnerRe since we announced the merger of equals at the end of January. And throughout this integration process, we have confirmed the premise of our merger, uncovered new opportunities and grown even more confident with respect to the tremendous strategic benefits of this merger.

Our strategic combination with PartnerRe will create superior and sustainable value to all shareholders by forming a broadly diversified global insurance and reinsurance company with the scale, capital and enhanced market presence to deliver greater breadth and depth of products and services, larger capacity and leading positions in several markets.

Together, we will be one of the world's preeminent specialty insurance and reinsurance companies with gross premiums written in excess of \$10 billion. As we detail on slide six, this is truly a transformational opportunity for our two companies.

By merging with PartnerRe, we are creating a company that will be one of the world's top specialty insurance and reinsurance companies with approximately \$13 billion of combined shareholders equity that, as Michael said, is a top five global reinsurance franchise with leading position in the broker channel, and top 10 global life and health reinsurer and a significant primary specialty insurance platform with compelling growth prospects across a diversified array of product lines.

We see significant potential to create value through our increased relevance with distribution partners and clients across our three major business units with one of the

most complete range of products and services, geographic spread, larger capacity and entrepreneurial spirit. And we are confident that we will achieve at least \$200 million in expense savings.

In addition, the transaction will significantly enhance capital generation capabilities through diverse sources of growth and profit which will allow us to both reinvest in the franchise as well as return meaningful capital to our shareholders.

Today's revised terms, as outlined on slide eight, reflect our steadfast commitment to the combination. Further terms of the amended amalgamation, PartnerRe common shareholders will receive a special one-time cash dividend of \$11.50 per share immediately prior to the closing of the merger.

The original terms of the amalgamation agreement remain unchanged. AXIS shareholders will receive one common share and PartnerRe shareholders will receive 2.18 common shares in the amalgamated company for each share they own.

Our combined board will include seven directors from each company including Jean-Paul Montupet currently the Chairman of PartnerRe, remaining as the Chairman of the combined company.

Following the close of the transaction, PartnerRe shareholders will own approximately 51.5% of the amalgamated company while AXIS shareholders will own approximately 48.5%. We expect the transaction to close in the third quarter of this year. And we've already received a few regulatory approvals including Hart-Scott-Rodino clearance.

As outlined on slide nine, we have made significant progress to-date which has reaffirmed the strategic benefits of the combination. We've already completed the first phase of integration, and as a result of this process, we are even more confident of achieving at least \$200 million in expense savings. The integration process has been extensive with active participation from both sides on over 20 identified work-streams. Our discussions have generated many excellent ideas that will benefit our merged company going forward. In addition, the positive feedback from brokers and clients with respect to the merger has been tremendous.

This transaction remains financially very compelling. As we note on slide 10, the transaction will result in expense synergies as well as significant capital generation and return to shareholders. It will be accretive to operating earnings per share and ROE to AXIS shareholders beginning in the first full year after the close. And we expect to achieve double-digit EPS accretion and double-digit ROE by year two. Book value per share dilution will be de minimis with very acceptable low-single-digit tangible book value per share dilution that we expect to quickly earn back.

The immense capital and cash flow generation capacity from the combination will more strongly position the combined company to invest in research and product development, to reinvest in its specialty franchises and growth businesses, invest in its staff to present the best team in the industry and to return meaningful capital to shareholders.

FINAL

Bloomberg Transcript

This transformative combination creates a leading global reinsurance platform, which will be increasingly important as consolidation in the reinsurance market continues and as you've heard from us before, increasingly cedants are focusing their reinsurance purchases to a smaller core panel of lead re-insurers.

Now I'd like to discuss some of the specific value creating aspects of this merger. On slide 12, you will note that the combination creates a business with over \$10 billion in total gross premiums with substantial strategic benefits. Upon the completion of the merger P&C reinsurance will comprise on a pro forma basis about 59% of our business, specialty insurance approximately 26% and life accident and health will represent 15%. Each of these three major businesses will benefit substantially from the markets positioning resulting from this combination.

As seen on slide 13, the two P&C reinsurance businesses combine to form a top five global P&C reinsurance business, and we will be the lead reinsurance based broker in the world.

Moving to slide 14, the combination of AXIS specialty insurance business with PartnerRe's insurance direct and facultative and wholesale insurance business will create a primary insurance platform with over \$2.5 billion in premiums. The global insurance business will have a balanced portfolio mix with strong focus on specialty lines and the potential to accelerate growth in desirable segments as opportunities arise.

Partner's life, accident and health business conflicts very little with AXIS A&H, as you can see on slide 15. The combined business will be a top 10 global life and health reinsurer and a top three U.S. health reinsurer, with significant opportunity for growth. The combined life A&H business offers the ability to leverage broad product capabilities for very high growth potential.

Between the two businesses, we have products to appeal to developed market demographics such as longevity and disability and to less developed market demographics such employee benefits and travel. The breadth of product is truly astounding and will allow us to create a leading value proposition wherever we go.

Healthcare is booming internationally. At AXIS, we've already begun to target new markets like the Middle East and specialist classes such as expats and high net worth individuals. In the U.S. both companies have been leaders in pursuing opportunities arising from the establishment of the Affordable Care Act, and our books complement each other very well. This combination of the two complementary franchises will feature global product development, one of the best actuarial teams in the industry and significant geographic reach. In addition, our hybrid insurance and reinsurance model offers significant advantages.

The new management team at the combined company on slide 16, which was previously announced, demonstrates how we plan to leverage the deep talent in both organizations. This is a very strong team that I know well. We've been working closely together on the

integration of our companies and we are committed to making it a success for all our stakeholders. We are looking forward to uniting as one company.

Moving to slide 18, I want to provide an update about our integration process. We are moving full steam ahead, approximately 150 people involved from both organizations working on over 20 separate work streams contributing to ensure the process moves as quickly and seamlessly as possible.

We have made significant progress in defining our vision and target operating model for our future, defined a day one scope requirement, and early indications strongly support accelerated achievement of strategic and operating objectives.

Slide 19 gives a breakdown of our clear path towards achieving this target. There are multiple opportunities for synergies across the organizations. As we've progressed through the first phase of integration, we've confirmed our initial assumptions and identified additional potential synergies that make us even more confident we will realize a minimum of \$200 million in merger-related savings.

On slide 20, you can see our highly complementary geographic footprint and business segment coverage with operations around the world, including North America, Europe, Asia, Australia, New Zealand, Latin America, the Caribbean and Africa. We will leverage each other's offices to accelerate geographic expansion. This global footprint offers opportunity to grow our business and where we have overlap, serves as a source of expense savings.

Some may ask, why not take advantage of the \$250 million breakup fee and go away? Simply accepting the \$250 million termination fee would represent only a one-shot deal with no strategic benefit to AXIS. The feedback we've received from clients, brokers and employees since the original announcement has only strengthened our conviction about the strategic power of this merger.

This transaction provides our companies with a tremendous opportunity to create substantial value immediately, and even more over time. By merging with PartnerRe we increase our scale and market presence. Our combined company will have approximately \$13 billion in combined shareholders' equity, over \$10 billion in combined gross premiums written across three attractive business platforms and sustainable long-term commercial growth prospects through combined scale, efficiencies and expanded product capability. Our expanded global platform and local market expertise will support and enhance growth opportunities.

As you can see on the last page, this transaction generates meaningful synergies including over \$200 million in identified actionable expense savings. We expect to achieve run rate level of savings within the first 18 months of the transaction. We feel that the strength of both companies' balance sheets, our shared conservative underwriting philosophies, strong reserve positions and the great familiarity between our management teams will limit the execution risk of this transaction.

Finally, the combination has the potential to increase our valuation by providing shareholders with an attractive entry point. We will have a stronger platform with earnings per share and ROE accretion driving sustainable value creation.

Now, we'd like to open up the call for questions. Operator?

Q&A

Operator

And our first question comes from Amit Kumar of Macquarie. Please go ahead.

Q - Amit Kumar {BIO 19777341 <GO>}

Thank you, good morning and thanks for the call.

A - Albert A. Benchimol {BIO 2023727 <GO>}

Good morning Amit.

Q - Amit Kumar {BIO 19777341 <GO>}

Just two quick questions. The first question regarding, I think we have some sense to this, how did you come up with the \$11.50 number? Was that more to maintain I guess book value growth equilibrium or maybe just talk about that number?

A - Albert A. Benchimol {BIO 2023727 <GO>}

And what's your second question?

Q - Amit Kumar {BIO 19777341 <GO>}

The second question is what I was getting this morning, was as an AXIS shareholder, I just saw \$560 million of potential capital from new company, move to PartnerRe shareholders. I'm curious what you would say to that?

A - Albert A. Benchimol {BIO 2023727 <GO>}

Okay, thank you for that. Let's address the first question. Obviously the derivation of the dividend took a lot of things into consideration. But, fundamentally as I mentioned earlier everything that we've seen from our earliest due diligence to the integration planning process has really gone very, very well and we've confirmed all of those benefits. And when we reviewed the expense synergies, the cash flow, the capital efficiencies available as a result of this merger and the fact that clearly, PartnerRe was listening to its shareholders and wanted to make sure, as we did, frankly, that all of the shareholders of both companies saw meaningful benefit in this merger. We felt it was appropriate to have PartnerRe declare the dividend of \$11.50.

FINAL

But importantly, Amit, even with this dividend we will have substantial capital to support our strong ratings, drive profitable growth and still continue with our plans to return our accumulated earnings to our shareholders through both regular dividends and stock repurchases. So we did not see any diminution of the potential of our company and the potential of our merger going through it.

Now with regards to the \$560 million, I think what we need to do is really two things. The first things that I would correct is that although there is a \$560 million dividend, the remaining company is going to be owned 52% by PartnerRe shareholders and 48% by AXIS shareholders. And so 52% of that reduction is actually absorbed by the PartnerRe shareholders. So as an AXIS shareholder if you look at the combined company after the merger, it's only approximately \$270 odd million which is a reduction.

And with that reduction, which I acknowledge, which does create, as I mentioned, only a very de minimis book value dilution and only low-single-digits tangible book value dilution, I believe that our shareholders are well served by owning a company that will be a formidable competitor going forward, having EPS accretion already in the first year, seeing double-digit EPS accretion within the second year, double-digit ROE over time. And as I said I expect that the benefits of this merger are such that we will very quickly earn back the very modest dilution that we took on tangible book value.

A - Michael A. Butt {BIO 1750135 <GO>}

And if I may add, our board obviously agreed with that analysis strongly.

Q - Amit Kumar {BIO 19777341 <GO>}

Got it. Okay. I'll stop here. Thanks for the answers.

A - Albert A. Benchimol {BIO 2023727 <GO>}

You are very welcome.

Operator

Our next question comes from Meyer Shields of KBW. Please go ahead.

Q - Meyer Shields {BIO 4281064 <GO>}

Thanks. Good morning. Albert, could you talk a little bit more specifically about the response you're seeing at 4/1 and how that plays in with your initial expectations?

A - Albert A. Benchimol {BIO 2023727 <GO>}

Yes, Mike, thank you. I think both PartnerRe and ourselves were very impressed by the reaction we got. As you might imagine we spent a long time throughout the last three months talking to brokers and talking to clients because one of the uncertainties as we were planning this merger was, as you all were asking, what are the potential dissynergies, and that was a number that we had - we were able to put a placeholder if you would, but this needed to be confirmed in the market.

FINAL

What I will tell you is that we grossly overestimated the dissynergies when we started this merger. Our clients and our brokers are highly enthusiastic about their merger. They see this as a real commitment to becoming a leader in the reinsurance space and they want to do more business with us, plain and simple.

In fact, I would argue that our underwriters on both sides and seeing the market response is actually emboldened them and made them feel increasingly comfortable about this merger going forward. We will be a much stronger competitor going forward. It's been – I have to say I've had fantastic meetings, which again, is why am so committed to making this merger work.

A - Michael A. Butt {BIO 1750135 <GO>}

If you believe in the tectonic plate shifts that some of you have all been talking about going on in the industry, then a lot of the thinking going into what we are doing relates to that and putting us in a position to be more strongly equipped to deal with those plate shifts.

A - Albert A. Benchimol {BIO 2023727 <GO>}

And by the way, the benefits that we've seen are not only on the reinsurance side. We've already seen significant benefits in our interactions with our brokers and clients on the insurance side and also on the A&H side. We've been – I'm very proud to say, we've been a very successful mid-sized company. This merger takes us into the top lead group, and we will be highly welcomed by our brokers and our clients in this top leadership group.

A - Michael A. Butt {BIO 1750135 <GO>}

Yes.

Q - Meyer Shields {BIO 4281064 <GO>}

Okay. That's very helpful. I just want to touch on one thing you said. I think we've all talked a lot, I understand well the panel reduction on the part of P&C reinsurers. Is there similar trend going on in the life reinsurance space?

A - Albert A. Benchimol {BIO 2023727 <GO>}

Actually, the life reinsurance space is a space that actually has smaller panels than the P&C space. There are actually smaller numbers of reinsurers in the world and they tend to have very strong relationships with their clients. So it's already there, if you would. I think there the benefit that we have – excuse me – is that if you look at the lead reinsurers in the world, they are essentially the top five, top six global reinsurers in the life world, and clients have significant concentration of business and receivables with those top reinsurers as it stands. The ability for the combined company to come with a life product offering and a \$13 billion equity base; again, will be very welcome by the clients because it provides a significant player to add to that too small a group of global life reinsurers.

Q - Meyer Shields {BIO 4281064 <GO>}

Okay. Thanks so much.

Operator

And our next question comes from Charles Sebaski of BMO Capital Markets. Please go ahead.

Q - Charles J. Sebaski {BIO 17349221 <GO>}

Good morning.

A - Albert A. Benchimol {BIO 2023727 <GO>}

Good morning, Charles.

Q - Charles J. Sebaski {BIO 17349221 <GO>}

I'm wondering first if you could talk at all about what the potential capital synergies are of the combined entity? I know you talked about the expense savings and your due diligence highlighting other, I was just wondering if you could point to any, or what the balance sheet synergies, capital relief could look like?

A - Albert A. Benchimol {BIO 2023727 <GO>}

Well, we can't quantify them for you here, but certainly we'll tell you that as we've been mentioning in a number of areas, the books are actually highly complementary. And so as you have this increasing complementation, you get diversification benefits across the book. Importantly, the ability to manage the overall book to make better purchases of reinsurance and retro, because as a larger buyer you get a lot more coverage from the market, and the ability to partner with third party capital to help deliver additional capital and potentially lower cost additional capital to our clients, are all ways that we'll reduce the overall - what I would say gross capital requirements of our company. And, of course, as a larger company with a broader range of products and services by industry, by line, by geography, we become a much more attractive partner to the third-party capital providers, which again only makes it easier for us to optimize the growth (26:18) and the net portfolio that we keep.

I think importantly, and I did not mention this in my prepared remarks, we have spoken to the rating agencies about our plans and about this dividend, and the feedback that we received was very positive. And I expect that the rating agencies see no issue with the declared dividend and our plans to continue to grow and return capital to our shareholders.

Q - Charles J. Sebaski {BIO 17349221 <GO>}

Could we talk - the dividend and the dollar amount at \$11.50, was this - were you comfortable at this level due to some of the further due diligence that has been taking place since you announced the deal, that, hey, we've gotten a better look at the books, we've gone through the reserve basis, we see where this is supported relative to where it was before?

And then additionally, what would be the comments some investors might have that, of the new company board makeup and the board members coming from the PartnerRe side saying that this kind of dividend should have been at the initial announcement of this transaction, as opposed to here, and that - it might question some that the board members are looking out for shareholder interest - on the PartnerRe side, not on your side. I think that people realize you struck a pretty attractive deal at the onset.

A - Albert A. Benchimol {BIO 2023727 <GO>}

There's a lot of stuff in your question so let's see if I can reduce it. Yes, the answer is yes. Everything that we've learned, and we've gone into depth a lot more, has certainly made us more comfortable that we could see this capital dividend go out of the company and still have no impact on our plans going forward, so a yes to your first part of your question.

With regard to the second part of your question, frankly, it's not up to me to discuss that. What I will tell you is that the PartnerRe management and directors have been staunch defenders of the interests of PartnerRe and its shareholders and where we are today is a deal that I believe provides significant value to the shareholders of both companies.

Q - Charles J. Sebaski {BIO 17349221 <GO>}

I appreciate your answers.

A - Albert A. Benchimol {BIO 2023727 <GO>}

Thank you.

Operator

And our next question comes from Josh Shanker of Deutsche Bank. Please go ahead.

Q - Josh D. Shanker {BIO 5292022 <GO>}

Yeah. Good morning. Following up on Charles's question just a little bit, and I absolutely agree with most everything he said, the one question I have for you Albert - which I am really not a lawyer and I don't understand these things completely, is there any risk of AXIS having engaged in collusion with PartnerRe given you already have 150 people dedicated to making this merger work and are there any legal implications to that?

A - Albert A. Benchimol {BIO 2023727 <GO>}

Josh, that question is so far out of line I wouldn't even know how to answer it.

Q - Josh D. Shanker {BIO 5292022 <GO>}

Well, then answer me now -

A - Albert A. Benchimol {BIO 2023727 <GO>}

No, no, let me finish it.

Q - Josh D. Shanker {BIO 5292022 <GO>}

Can you explain why it's not an issue - I would love to know why it's not an issue. I don't understand I am not - help us out.

A - Albert A. Benchimol {BIO 2023727 <GO>}

Let me finish it.

Q - Josh D. Shanker {BIO 5292022 <GO>}

Thanks.

A - Albert A. Benchimol {BIO 2023727 <GO>}

We have an amalgamation agreement, which we signed with the two companies. We have confidentiality agreements, which we signed with the two companies and we have followed to the letter of the law and the spirit of the law all protection of confidential information going forward. There is nothing wrong with two companies proceeding with integration work prior to the close of a transaction.

Operator

Thank you. Our next question comes from Jay Cohen of Merrill Lynch. Please go ahead.

Q - Jay Arman Cohen {BIO 1498813 <GO>}

Yes. Thank you. On the capital return, Albert, you talked about returning the accumulated earnings to shareholders through buybacks and dividends. Is that just on the AXIS side or are you speaking for the entire company, for the PartnerRe accumulated earnings as well?

A - Albert A. Benchimol {BIO 2023727 <GO>}

Jay, good morning, I'm talking about the accumulated earnings of both companies. As you know, both companies have been very good stewards of capital and my understanding is that both companies were prepared to return all of their earnings to their shareholders during the year.

Now we did suspend the share repurchase on the announcement of the merger, but since then we've been accruing a lot of earnings that we do not believe we need either on a standalone basis or on a combined basis. And as soon as the merger is closed we will be re-initiating capital management activities and it remains our intention to return to our shareholders immediately after the close our accumulated joint earnings of the company.

Q - Jay Arman Cohen {BIO 1498813 <GO>}

Great, that's all I needed. Thanks for the clarification.

A - Albert A. Benchimol {BIO 2023727 <GO>}

You are welcome.

Operator

And our next question comes from Ian Gutterman of Balyasny. Please go ahead.

Q - Ian J. Gutterman {BIO 18249218 <GO>}

Hi, thank you. First Albert, I think - correct me if I'm wrong here - but I think in the original presentation you did not say this was double-digit EPS accretive. Am I correct that this is new this time?

A - Albert A. Benchimol {BIO 2023727 <GO>}

I'd have to recall, but I think that - I don't remember what we said but I think that the accretion to the organization really hasn't changed much between the original model and what we have now.

Q - Ian J. Gutterman {BIO 18249218 <GO>}

That's what I was trying to get at, okay. It's just I didn't see that in the slides. I couldn't remember if you verbally said it or not. '

And then secondly, I don't see, at least yet, any comment from Exor, whether they're going to withdraw their offer or not. If they don't and they want to leave that offer out there and this goes to a vote on the PartnerRe side, what - if that were to happen and PartnerRe were to lose the vote with you, do you still get your breakup fee?

A - Albert A. Benchimol {BIO 2023727 <GO>}

As I understand the terms of the agreement, if the PartnerRe shareholders vote down this deal and then subsequently do a transaction in the subsequent 12 months, we would get the entire breakup fee of \$280 million plus the reimbursement of expenses.

Q - Ian J. Gutterman {BIO 18249218 <GO>}

Okay, so I guess - if it was voted - I mean, obviously, you get into games of chicken with this stuff - if they vote it down but then PartnerRe chooses to remain independent you would get something less?

A - Albert A. Benchimol {BIO 2023727 <GO>}

If they chose to remain independent we would get a vote down fee of \$55 million plus reimbursement of expenses. But obviously, I'm quite confident that the shareholders of PartnerRe will see the merits of this merger and the value creation and so I'm very optimistic, Ian, that the shareholders of PartnerRe will vote to support this transaction.

Q - Ian J. Gutterman {BIO 18249218 <GO>}

No, of course. I just wanted to understand the ramifications because these things get complicated sometimes. That's all I had. Thank you.

A - Albert A. Benchimol {BIO 2023727 <GO>}

Thank you.

Operator

Our next question comes from Brian Meredith from UBS. Please go ahead.

Q - Brian R. Meredith {BIO 3108204 <GO>}

Hey, good morning. Albert, just quickly, so I think last time we had one of these calls, a question was getting commitment to obviously the primary insurance business and that being a larger percentage of your overall business and I think you said yeah, you'd like that to be the case over time, at least 50/50 or more. I'm just curious: how do you expect to get to that kind of 50/50 or more? Is that an organic growth? Do you think there is additional acquisition to come here down the road?

A - Albert A. Benchimol {BIO 2023727 <GO>}

I think we have a - thank you for that question, Brian. I think we have a wide range of opportunities. I think organically, we will be able to grow more because of our positioning, of our breadth of products, capital, locations and all the benefits that I have enunciated in the beginning of this presentation. But there's no question that with a company of the size that we will have, the potential profitability and cash flow here is very large.

And so, certainly we'll also have the ability to make acquisitions if there are attractive acquisitions available going forward. But that, as at all times, will be based on the opportunities in front of us and the benefits of investing our capital to support growth organically, to support growth by acquisitions or to return that capital back to our shareholder. You've got our commitment that we will make the best decisions we can at that time.

Q - Brian R. Meredith {BIO 3108204 <GO>}

Great, thanks for the answer.

A - Albert A. Benchimol {BIO 2023727 <GO>}

You're welcome Brian. Thank you.

Operator

This concludes the question-and-answer session. At like to turn the call back over to Albert Benchimol for any closing remarks.

A - Albert A. Benchimol {BIO 2023727 <GO>}

Well, thank you very much for joining us. We are obviously very excited and very committed with our upcoming merger with PartnerRe. We believe that we are creating one of the more successful leading companies in the P&C space. And we look forward to reporting to you on our progress as time goes by. Have a great day.

A - Michael A. Butt {BIO 1750135 <GO>}

Thank you all. Take care.

Operator

And we thank you for your time. Today's conference has now concluded. And we thank you all for attending today's presentation. You may now disconnect.

This transcript may not be 100 percent accurate and may contain misspellings and other inaccuracies. This transcript is provided "as is", without express or implied warranties of any kind. Bloomberg retains all rights to this transcript and provides it solely for your personal, non-commercial use. Bloomberg, its suppliers and third-party agents shall have no liability for errors in this transcript or for lost profits, losses, or direct, indirect, incidental, consequential, special or punitive damages in connection with the furnishing, performance or use of such transcript. Neither the information nor any opinion expressed in this transcript constitutes a solicitation of the purchase or sale of securities or commodities. Any opinion expressed in the transcript does not necessarily reflect the views of Bloomberg LP. © COPYRIGHT 2022, BLOOMBERG LP. All rights reserved. Any reproduction, redistribution or retransmission is expressly prohibited.

FINAL

Bloomberg Transcript